In the present study we investigated whether the
neuropeptide nociceptin/orphanin FQ (N/OFQ), previously implicated in the pathogenesis of
Parkinson's disease, also affects
L-DOPA-induced
dyskinesia. In striatal slices of naive rodents, N/OFQ (0.1-1 μm) prevented the increase of ERK phosphorylation and the loss of depotentiation of synaptic plasticity induced by the D1 receptor agonist
SKF38393 in spiny neurons. In vivo, exogenous N/OFQ (0.03-1 nmol, i.c.v.) or a synthetic N/
OFQ receptor agonist given systemically (0.01-1 mg/Kg) attenuated
dyskinesias expression in
6-hydroxydopamine hemilesioned rats primed with
L-DOPA, without causing primary hypolocomotive effects. Conversely, N/
OFQ receptor antagonists worsened
dyskinesia expression. In vivo microdialysis revealed that N/OFQ prevented
dyskinesias simultaneously with its neurochemical correlates such as the surge of nigral
GABA and
glutamate, and the reduction of thalamic
GABA. Regional microinjections revealed that N/OFQ attenuated
dyskinesias more potently and effectively when microinjected in striatum than substantia nigra (SN) reticulata, whereas N/
OFQ receptor antagonists were ineffective in striatum but worsened
dyskinesias when given in SN. Quantitative autoradiography showed an increase in N/
OFQ receptor binding in striatum and a reduction in SN of both unprimed and dyskinetic
6-hydroxydopamine rats, consistent with opposite adaptive changes of N/OFQ transmission. Finally, the N/
OFQ receptor synthetic agonist also reduced
dyskinesia expression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated dyskinetic macaques without affecting the global parkinsonian score. We conclude that N/
OFQ receptor agonists may represent a novel strategy to counteract
L-DOPA-induced
dyskinesias. Their action is possibly mediated by upregulated striatal N/
OFQ receptors opposing the D1 receptor-mediated overactivation of the striatonigral direct pathway.